Research Paper Volume 14, Issue 17 pp 7038—7051
The downregulated drug-metabolism related ALDH6A1 serves as predictor for prognosis and therapeutic immune response in gastric cancer
- 1 Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
- 2 General Surgery Department, Second Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
- 3 Department of Pathology, Xiangya Changde Hospital, Changde 415000, Hunan, China
- 4 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
- 5 Department of Orthopedic Surgery, The Second Hospital University of South China, Hengyang 421001, Hunan, China
- 6 Department of Emergency, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
- 7 Department of Emergency, Xiangya Changde Hospital, Changde 415000, Hunan, China
- 8 Department of General Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
Received: May 23, 2022 Accepted: August 24, 2022 Published: September 12, 2022
https://doi.org/10.18632/aging.204270How to Cite
Copyright: © 2022 Cai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Drug metabolism-associated genes have been clarified to play a vital role in the process of cancer cell growth and migration. Nevertheless, the correlation between drug metabolism-associated genes and gastric cancer (GC) has not been fully explored and clarified. This paper has focused on the role of aldehyde dehydrogenase 6 family member A1 (ALDH6A1), a drug metabolism-associated gene, in the immune regulation and prognosis of GC patients. Using several bioinformatics platforms and immunohistochemistry (IHC) assay, we found that ALDH6A1 expression was significantly down-regulated in GC tissues. Moreover, higher expression of ALDH6A1 was related to the better prognosis of GC patients. ALDH6A1 was also found to be involved in the regulation of several immune-associated signatures, including immunoinhibitors. In conclusion, the above results have concluded that aberrant expression of ALDH6A1 might be served as the promising predictor for prognosis and clinical immunotherapy response in GC patients.